{"id":28565,"date":"2022-09-27T03:45:36","date_gmt":"2022-09-27T03:45:36","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=28565"},"modified":"2022-12-11T23:16:19","modified_gmt":"2022-12-11T23:16:19","slug":"prescient-therapeutics-investor-replay-cellpryme-a","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/","title":{"rendered":"Prescient Therapeutics Investor Replay &#8211; CellPryme-A"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gmd7651c9 gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gm624ce9e\" class=\"wp-block-gutentor-m4 section-gm624ce9e gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm1a3975\" class=\"wp-block-gutentor-m4-col col-gm1a3975 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm1a3975\" class=\"section-gm1a3975 gutentor-col-wrap\">\n<h2 class=\"has-text-align-center has-white-color has-text-color wp-block-heading\" style=\"font-size:33px\">Prescient Therapeutics CellPryme-A Briefing<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm683ebcc\" class=\"wp-block-gutentor-m4 section-gm683ebcc gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gme86ac4\" class=\"wp-block-gutentor-m4-col col-gme86ac4 gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gme86ac4\" class=\"section-gme86ac4 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\" alt=\"\" class=\"wp-image-28552\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/754136770?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/reachmarkets.com.au\/wp-content\/uploads\/2019\/12\/play-icon-white.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm2a03a6\" class=\"wp-block-gutentor-m4-col col-gm2a03a6 gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm2a03a6\" class=\"section-gm2a03a6 gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\">Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of Scientific Affairs Dr Rebecca Lim provide an overview of the second component of Prescient\u2019s cell therapy enhancement platform; CellPryme-A.<\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">In this session, they discuss:<\/p>\n\n\n\n<ul class=\"white wp-block-list\"><li>An introduction to Prescient\u2019s newest cell therapy enhancement platform, CellPryme-A<\/li><li>The compelling data for the CellPryme-A platform to boost the effectiveness of CAR-T therapies \u2013 especially in difficult solid tumours<\/li><li>How CellPryme-A synergises with CellPryme-M and complements Prescient\u2019s next-gen CAR-T platform OmniCAR<\/li><\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 27 September 2022 at 12:00pm (AEST)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gm616e262 gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"speak has-text-color wp-block-heading\" style=\"color:#ffcc00\">Featured Speakers<\/h4>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\"><\/h3>\n\n\n\n<section id=\"gm54f1cad\" class=\"wp-block-gutentor-m4 section-gm54f1cad gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm317146\" class=\"wp-block-gutentor-m4-col col-gm317146 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm317146\" class=\"section-gm317146 gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gm42e932\" class=\"wp-block-gutentor-m4-col col-gm42e932 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm42e932\" class=\"section-gm42e932 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg\" alt=\"\" class=\"wp-image-27331\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped-150x150.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\">Steven Yatomi-Clarke<\/h3>\n\n\n\n<h4 class=\"has-text-align-center speaker-title has-white-color has-text-color wp-block-heading\">CEO and Managing Director<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmecc2fb\" class=\"wp-block-gutentor-m4-col col-gmecc2fb gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gmecc2fb\" class=\"section-gmecc2fb gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full is-resized speaker-img\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Rebecca-Lim-2-scaled-e1670798280688.jpg\" alt=\"\" class=\"wp-image-29115\" width=\"300\" height=\"306\"\/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\">Dr Rebecca Lim<\/h3>\n\n\n\n<h4 class=\"has-text-align-center speaker-title has-white-color has-text-color wp-block-heading\">Senior Vice President of Scientific Affairs <\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmfcdbe3\" class=\"wp-block-gutentor-m4-col col-gmfcdbe3 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gmfcdbe3\" class=\"section-gmfcdbe3 gutentor-col-wrap\"><\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":28552,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-28565","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prescient Therapeutics Investor Replay - CellPryme-A - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics Investor Replay - CellPryme-A - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T03:45:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-11T23:16:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Daniella Watson\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Daniella Watson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/\"},\"author\":{\"name\":\"Daniella Watson\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\"},\"headline\":\"Prescient Therapeutics Investor Replay &#8211; CellPryme-A\",\"datePublished\":\"2022-09-27T03:45:36+00:00\",\"dateModified\":\"2022-12-11T23:16:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/\"},\"wordCount\":217,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/\",\"name\":\"Prescient Therapeutics Investor Replay - CellPryme-A - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\",\"datePublished\":\"2022-09-27T03:45:36+00:00\",\"dateModified\":\"2022-12-11T23:16:19+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics Investor Replay &#8211; CellPryme-A\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\",\"name\":\"Daniella Watson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"caption\":\"Daniella Watson\"},\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/daniella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics Investor Replay - CellPryme-A - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics Investor Replay - CellPryme-A - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/","og_site_name":"PTX Therapeutics","article_published_time":"2022-09-27T03:45:36+00:00","article_modified_time":"2022-12-11T23:16:19+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png","type":"image\/png"}],"author":"Daniella Watson","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Daniella Watson","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/"},"author":{"name":"Daniella Watson","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d"},"headline":"Prescient Therapeutics Investor Replay &#8211; CellPryme-A","datePublished":"2022-09-27T03:45:36+00:00","dateModified":"2022-12-11T23:16:19+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/"},"wordCount":217,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/","name":"Prescient Therapeutics Investor Replay - CellPryme-A - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png","datePublished":"2022-09-27T03:45:36+00:00","dateModified":"2022-12-11T23:16:19+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-cellpryme-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics Investor Replay &#8211; CellPryme-A"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d","name":"Daniella Watson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","caption":"Daniella Watson"},"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/daniella\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/28565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=28565"}],"version-history":[{"count":12,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/28565\/revisions"}],"predecessor-version":[{"id":29282,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/28565\/revisions\/29282"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/28552"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=28565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=28565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=28565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}